Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents

Mariottini, Alice; Forci, Benedetta; Gualdani, Elisa; Romoli, Monica; Repice, Anna Maria; Barilaro, Alessandro; Mechi, Claudia; Massacesi, Luca; Francesconi, Paolo

doi:10.1016/j.msard.2022.103679

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After removal of duplicates, 853 studies remained, and 62 full-text articles were reviewed after screening. Finally, 15 cohort studies were enrolled in our study, which included 173,565 female MS patients ( Midgard et al, 1996 ; Sumelahti et al, 2004 ; Achiron et al, 2005 ; Nielsen et al, 2006 ; Bahmanyar et al, 2009 ; Hemminki et al, 2012 ; Kingwell et al, 2012 ; Sun et al, 2014 ; Hajiebrahimi et al, 2016 ; Etemadifar et al, 2017 ; Nørgaard et al, 2019 ; Grytten et al, 2020 ; Johnson et al, 2021 ; Marrie et al, 2021 ; Bosco-Lévy et al, 2022 ; Mariottini et al, 2022 ). The quality scores of all studies were no more than 6.…”

Section: Resultsmentioning

confidence: 99%

“…The etiology of MS is unclear, but it is currently thought to be an immune-mediated demyelinating disease involving the central nervous system ( Mariottini et al, 2022 ; Stampanoni Bassi et al, 2022 ). MS and breast cancer share some common features; most notably, the incidence of both diseases is much higher in women than in men ( O’Malley et al, 2015 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple sclerosis and breast cancer risk: a meta-analysis of observational and Mendelian randomization studies

Fang

Zhang

Zhou

et al. 2023

Front. Neuroinform.

View full text Add to dashboard Cite

BackgroundSeveral observational studies have explored the relationships between multiple sclerosis (MS) and breast cancer; however, whether an association exists remains unknown.MethodsWe conducted a meta-analysis of observational studies and Mendelian randomization (MR) based on genetic variants to identify the relationship between MS and breast cancer. The observational studies were searched from PubMed, Embase, Web of Science, and Scopus to assess the relationship between MS and breast cancer from inception to 07 Nov 2022. Moreover, we explored the association between genetically pre-disposed MS and breast cancer risk based on an MR study. The summary analysis for MS from two separate databases [International Multiple Sclerosis Genetics Consortium (IMSGC), FinnGen] and the summary analysis for breast cancer from Breast Cancer Association Consortium.ResultsFifteen cohort studies involving 173,565 female MS patients were included in this meta-analysis. The correlation between MS and breast cancer was not statistically significant [relative ratio (RR) = 1.08, 95% confidence interval (CI) = 0.99–1.17]. In the MR analysis, we did not observe causal associations of genetically determined MS with breast cancer and its subtypes from both the IMSGC and FinnGen datasets.ConclusionThe meta-analysis of observational and MR based on genetic variants does not support the correlation between MS and breast cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Multiple sclerosis and breast cancer risk: a meta-analysis of observational and Mendelian randomization studies

Fang

Zhang

Zhou

et al. 2023

Front. Neuroinform.

View full text Add to dashboard Cite

show abstract

“…Across studies there is also a lack of uniformity as to which therapies are included. Several studies have included therapies such as azathioprine and cyclophosphamide in the analysis for immunosuppressive therapies (22,26,50,51,53,55,56). These therapies have been widely reported to increase the risk of cancer (59,60), and are seldom used in the modern-day treatment of MS, thereby likely skewing results.…”

Section: Disease Modifying Therapies and Risk Of Cervical Cancermentioning

confidence: 99%

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies

Bridge

Brotherton²,

Foong³

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

There is a growing need to better understand the risk of malignancy in the multiple sclerosis (MS) population, particularly given the relatively recent and widespread introduction of immunomodulating disease modifying therapies (DMTs). Multiple sclerosis disproportionately affects women, and the risk of gynecological malignancies, specifically cervical pre-cancer and cancer, are of particular concern. The causal relationship between persistent human papillomavirus (HPV) infection and cervical cancer has been definitively established. To date, there is limited data on the effect of MS DMTs on the risk of persistent HPV infection and subsequent progression to cervical pre-cancer and cancer. This review evaluates the risk of cervical pre-cancer and cancer in women with MS, including the risk conferred by DMTs. We examine additional factors, specific to the MS population, that alter the risk of developing cervical cancer including participation in HPV vaccination and cervical screening programs.

show abstract

Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies

Bridge,

Brotherton,

Stankovich

et al. 2024

Neurology

View full text Add to dashboard Cite

Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents

Cited by 3 publications

References 23 publications

Multiple sclerosis and breast cancer risk: a meta-analysis of observational and Mendelian randomization studies

Multiple sclerosis and breast cancer risk: a meta-analysis of observational and Mendelian randomization studies

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies

Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies

Contact Info

Product

Resources

About